http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
중국 조선족 화자가 발음한 한국어 어두 파열음의 음향적 특성 연구
JIN AI HUA,JIN YANG 학습자중심교과교육학회 2021 학습자중심교과교육연구 Vol.21 No.2
본 연구는 중국 조선족 화자가 발음하는 어두 파열음의 VOT와 음의 높낮이로 나타내는 후행모음의 F0의 값을 분석하여 음향학적 특성을 밝히고, 한국인의 어두 파열음과의 차이를 살펴보는데 목적을 둔다. 본 연구에서는 10명의 조선족 화자가 발음한 어두 파열음의 VOT와 후행모음의 F0을 분석하였다. 그 결과 경음은 VOT에 의해 나머지 발성 유형과 변별할 수 있다. 격음의 VOT는 조선족 화자가 더 길고, 평음은 한국인의 VOT가 더 길게 나왔다. 한국인과 조선족 화자가 발음한 VOT는 성별에 대해 모두 차이를 보이지 않는다. 다음 전반적으로 평음의 후행모음의 F0으 나머지 두 발성 유형보다 낮은 수치를 보인다. 조선족 화자의 F0은 한국인보다 더 높다. 한국인과 조선족 화자는 성별에 관계없이 모두 평음의 F0이 가장 낮지만, 조선족 여성의 경우는 경음이 평음보다 조금 낮았다. This study aims to reveal the acoustic characteristics by analyzing the VOT of the pronouncing rupture sound pronounced by Chinese Korean speakers and the F0 value of the trailing vowel expressed by the pitch of the sound, and to examine the difference between the plosives of Koreans. In this study, the VOT and F0 of the trailing vowels were analyzed by 10 Korean-Chinese speakers. As a result, the hard sound can be distinguished from the rest of the vocal types by VOT. The Korean-Chinese speaker was longer in the abbreviated VOT, and the Korean VOT for the plain-eum was longer. VOT, pronounced by Korean and Korean-Chinese speakers, shows no difference in gender. Next, overall, the F0 of the trailing vowel of the plain tone is lower than the other two vocal types. The F0 of Korean-Chinese speakers is higher than that of Koreans. Both Korean and Korean-Chinese speakers had the lowest F0 of plain tone regardless of gender, but Korean-Chinese women had a slightly lower hard note than plain tone.
Han Ying-Hao,Mao Ying-Ying,Yu Nan-Nan,Jin Mei-Hua,Jin Ying-Hua,Wang Ai-Guo,Zhang Yong-Qing,Shen Gui-Nan,Cui Yu-Dong,Yu Li-Yun,Lee Dong-Seok,Jo Yu-Jin,Sun Hu-Nan,Kwon Jeongwoo,권태호 한국응용생명화학회 2020 Applied Biological Chemistry (Appl Biol Chem) Vol.63 No.3
In this study, we used RNA sequencing (RNA-seq) to analyze and compare bulk cell samples from wild-type (WT) dermal mesenchymal stem cells (DMSCs) (n = 3) and Prx II knockout DMSCs (n = 3). The purpose of the study was to elucidate the role of Prx II on allogeneic immune rejection of transplanted DMSCs. The results revealed differential expression of 472 genes (176 up-regulated and 296 down-regulated; p ≤ 0.05) between the PrxII+/+ (WT) and PrxII−/− sample groups. When highly regulated genes were categorized according to the Gene Ontology (GO) molecular function classification and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, the PrxII−/− samples showed a robust downward trend in allograft rejection. The study identified 43 all immunologically rejected differentially expressed genes, of which 41 showed lower expression in the PrxII−/− vs. PrxII+/+ (WT) samples. These findings suggest that Prx II gene knockout may down-regulate the allograft rejection that occurs during DMSCs transplantation and improve the survival rate of DMSCs in the host. This study provides a new perspective on the clinical treatment of stem cell transplantation.
Liu, Ai-Na,Sun, Ping,Liu, Jian-Nan,Ma, Jin-Bo,Qu, Hua-Jun,Zhu, Hua,Yu, Cai-Yan,Zhang, Liang-Ming Asian Pacific Journal of Cancer Prevention 2012 Asian Pacific journal of cancer prevention Vol.13 No.4
Objective: To study the relationship between clinical pathologic characteristics, treatment modalities and prognostic factors in HER-2 (Human Epidermal growth factor Receptor-2) overexpressed breast carcinoma. Materials and Methods: Major clinico-pathological factors including therapeutic modalities and survival status of 371 breast cancer patients with HER2 over-expression, teated at Yantai Yuhuangding Hospital from March of 2002 to December of 2010 were retrospectively studied, with special attention focused on survival-related factors. Results: The median age of the total 371 patients in this study was 48 years at time of diagnosis, among which, the leading pathological type was infiltrating ductal carcinoma (92.5%); 62.8% presented with a primary tomor larger than 2 cm in diameter at diagnosis, 51.0% had axillary lymph node (ALN) metastases; ER (Estrogen receptor)/PR (Progesterone receptor) double negative occured in 52.8% of cases, and PCNA (proliferation cell nuclear antigen) (+++) was found in 55.1%. HER-2 overexpressed patients were usually in advanced stage when the diagnosis was made (72.8% at stages IIA~IIIC). The prognosis and survival were assessed in 259 patients with complete follow-up data. 5-year DFS (disease-free survival) and OS (overall survival) rate was 68.0% and 78.0% respectively. Univariate analysis revealed that age, tumor size, ALN metastases, LVSI (lymph-vascular space involvement), PCNA status, hormonal therapy, chemotherapy cycles, and HER-2 overexpression, correlated closely with the prognosis. ALN metastases, LVSI, PCNA status and chemotherapy cycles were independent predictors of survival. Conclusions: HER-2 overexpressed breast cancer has special clinical and pathological characteristics, with advanced clinical stages and high rate of ER/PR double negative. Lymph node metastases, LVSI, PCNA and chemotherapy cycles are independent predictors of prognosis.